Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec;10(4):577-86.
doi: 10.1208/s12248-008-9068-x. Epub 2008 Dec 11.

P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?

Affiliations

P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?

Praveen V Balimane et al. AAPS J. 2008 Dec.

Abstract

The objective was to directly compare the four different "calculation" methods of assessing P-gp inhibition potential using experimental data obtained from approximately 60 structurally diverse internal research and marketed compounds. Bidirectional studies for digoxin (probe for P-gp substrate) were performed with and without test compounds (at 10 microM). Four different calculation methods were applied to the same dataset (raw bidirectional permeability values) to obtain the "percent inhibition of P-gp" for these compounds using the different methods. Significantly different inhibition potential was obtained with the "exact" same experimental dataset depending on the calculation method used. Subsequently, entirely different conclusions regarding the "inhibition potential" of test compound was reached due to the different calculation methods. Based on the direct comparison of these methods, method no. 3 (i.e., inhibition of B to A permeability of digoxin) is recommended as the calculation method ideal during screening stages due to its high throughput amenability. The methodology is capable of rapidly screening compounds with adequate reliability for early stage drug discovery. Method no. 3 provides an abridged version of a bidirectional study that is fully capable of identifying all non-inhibitors (0-20%), moderate inhibitors (20-60%), and potent inhibitors (>60%) and demonstrates high correlation with method no. 1 (inhibition based on both A to B and B to A permeability of digoxin). Nevertheless, method no. 1 might be appropriate for more detailed mechanistic studies required in late stage discovery and development.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Correlation of “percent P-gp inhibition” values obtained via the four different calculation methods for internal research and marketed compounds. Percent P-gp inhibition values were calculated using the bidirectional permeability values for digoxin (alone as well as in presence of 10 μM test compound). Parameters obtained were: b(0) = intercept, b(1) = slope, r 2 = regression
Fig. 2
Fig. 2
Bidirectional permeability values for digoxin in presence and absence of putative non-inhibitors of P-gp. Each column represents the mean ± SD of at least three data points
Fig. 3
Fig. 3
Bidirectional permeability values for digoxin in presence and absence of test compounds that result in a final efflux ratio ~5. Each column represents the mean ± SD of at least three data points (* = A to B permeability in presence of test compound is significantly higher than A to B for digoxin control, # = B to A permeability in presence of test compound is significantly lower than B to A for digoxin control; p < 0.05)

References

    1. Leahey E., et al. Interaction between quinidine and digoxin. JAMA. 1978;240:533–534. doi: 10.1001/jama.240.6.533. - DOI - PubMed
    1. Lin J. Drug–drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev. 2003;55:53–81. doi: 10.1016/S0169-409X(02)00171-0. - DOI - PubMed
    1. Lin J., Yamazaki M. Role of P-glycoprotein in pharmacokinetics. Clin Pharmacokinet. 2003;42:59–98. doi: 10.2165/00003088-200342010-00003. - DOI - PubMed
    1. Matheny C., Lamb M., Brouwer K., Pollak G. Pharmacokinetic and pharmacodynamic implications of P-gp modulation. Pharmacotherapy. 2001;21:778–796. doi: 10.1592/phco.21.9.778.34558. - DOI - PubMed
    1. Polli J., et al. Role of P-gp on CNS disposition of amprenavir, an HIV protease inhibitor. Pharm. Res. 1999;16:1206–1212. doi: 10.1023/A:1018941328702. - DOI - PubMed

MeSH terms

LinkOut - more resources